You are invited to a breakfast meeting on 12^th August to examine

The Influence of CAMS Regulations on business practice

The discussion will be led by Ansie Savrda of Execu Regulatory Services and cover the following topics

• Licensing of Applicant , manufacturing facilities, analytical laboratories;
• CAMS Product Development;
• Submitting dossiers- practical tips;
• Analytical Methods;
• Stability testing;
• Raw material , final product assessment and batch Release
•  Post Registration Obligations (P&A);
• Marketing material

Who will benefit? Regulatory, Quality, Logistic and Marketing  personnel

Time: 0830

Venue: NAPM Offices, 1342 Howick Mews, Waterfall Park, Bekker Road, Midrand

RSVP by 29^th July 2015 to Vuyokazi at vuyo (at) napm.co.za or  011 312 6966

Please book early as places are limited.

I...

Download (PDF, 4.62MB)

Download (PDF, 2.98MB)

Johannesburg, 17^th July 2014

The National Association of Pharmaceutical Manufacturers (NAPM) has proposed a zero Value Added Tax(VAT) rating of medicines in its submission to the Davis Tax Committee, tasked with assessing the country’s tax policy framework and its role in supporting the objectives of inclusive growth, employment, development and fiscal sustainability in South Africa.

Although the proposed Zero VAT rating requested consideration for all medicines it  particularly targets Schedule 3 to Schedule 6 medicines, which are prescribed for serious illnesses,.  As indicated by the latest World Health Organisations WHO/HAI Global Pharmaceutical Policy Brief 5, taxes levied on medicines commonly make up 20 – 30 % of the final price consumers pay for medicines.

The NAPM strongly ...

LTR Sean Martin (Activo), Des Brothers (Ranbaxy), Anita Smal (Abex), Muhammad Bodhania (Medreich),Paul Anley (Pharma Dynamics, Vivian Frittelli (NAPM),Herman Grobler (Cipla), Gaurav Jain (Zydus), Suhail Gani (Austell), Nihar Patnaik (Dr Reddys)
Absent Kingsley Tloubatla.

Johannesburg, 25^th June 2014

The National Association of Pharmaceutical Manufacturer’s (NAPM) is pleased to announce the appointment of its new Executive Council (EXCO), which has been tasked strengthening the association’s strategic position within the pharmaceutical industry whilst representing the interests of its members and the broader public. Established in 1977, the NAPM comprises generics-based pharmaceutical manufacturers and distributors...

17th Annual IGPA Conference

November 19-21, 2014: Join us for the 17th Annual IGPA Conference! The biggest conference gathering of the global generic industry, attracting attendees from around the globe. It will convene at the beautiful Key Biscayne, Florida. The program agenda provides a unique forum for generic pharmaceutical executives from around the world to network and hear world-renowned experts discussing the latest insight into the international commercial, legal, and regulatory developments concerning the generic pharmaceutical sector. Register Today!

Website: http://www.gphaonline.org/events/upcoming-events/17th-annual-igpa-conference

Agenda: http://www.gphaonline.org/media/wysiwyg/Meetings/IGPA_2014/IGPA_-_Agenda.pdf

Registration: https://www.cvent...

The inaugural Manufacturing Indaba will be held on 19 & 20 May 2014 at Emperors Palace in Johannesburg, South Africa.

South Africa needs to enhance its manufacturing competiveness and aid in strengthening the GDP given the fact that it is the second biggest economic sector. Although South Africa’s manufacturing output rose 2.2 percent year on year in volume terms in May this year, more needs to be done to eliminate obstacles local manufacturers have had to face to remain competitive with their counterparts in other countries.

Drivers such as innovation, costs of labour and materials, supplier networks, economy and trade, infrastructure and government investments all play a role in increasing global competitiveness.

The Manufacturing Indaba, together with its strategic partner The Manufac...

L to R Dr Anban Pillay, Tommy Scott, Gaurav Jain, Herman Grobler, Vivian Frittelli, Dr Skhumbuzo Ngozwana, Hon Dr Aaron Motsoaledi, Nihar Patnaik, Muhammad Bodhania, Anita Smal

&&&&&&&&&&&

The Executive Committee of the NAPM met with the Minister of Health Dr Aaron Motsoaledi at the end of March to discuss the role of the generic medicines industry in providing access to affordable medicine in South Africa. The Minister stressed the importance of the draft intellectual policy and indicated that legislation would be inacted as promptly as possible. He also reiterated that with the doubling of the HIV/aids treatment campaign and the new initiative to provide TB treatment to more patients, the  generics industry would play a vital role in healthcare in the country.

The National Association of Pharmaceutical Manufacturers

Which represents many of the generic medicine suppliers in this country would like to offer our support to the sentiments expressed by Minister Davies in his press statement on the Draft IP Policy.

His statement falls in line with the mission of our Association- to provide greater access to affordable, quality and safe medicine to the citizens of South Africa.

We trust that the Minister’s colleagues in the National Department Of Health will amend policies, regulations and practices to facilitate his policy objectives regarding the issues of licensing and parallel importation.

DATE: 5 NOVEMBER 2013

 TO: ALL NEWS EDITORS AND JOURNALISTS

 MEDIA STATEMENT BY MINISTER ROB DAVIES ON THE NATIONAL IP POLICY AND REMOVAL OF ADVERSE CREDIT...

The NAPM held a workshop for healthcare practitioners at the Johannesburg Country Club on 17th October 2013. Entitled Generics, Get the Facts Straight, the workshop discussed the manner in which generic medicines were developed and registered in South Africa. One of the arguments given by detractors of generic medicines is that these medicines are not tested in human beings. Professor Jacques Snyman, former head of the department of Clinical Pharmacology at the Steve Biko School of Medicine, described how bioequivalence studies are carried out, He referred to trials which showed overall differences between standards in branded medicines and generic equivalents to be in the region of 3,5%...